Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis

Am J Rhinol Allergy. 2011 Jul-Aug;25(4):e149-52. doi: 10.2500/ajra.2011.25.3620.

Abstract

Background: Vasomotor rhinitis (VMR) is a hypersensitivity syndrome with heightened reactivity to environmental triggers.

Methods: Twenty-two patients with severe VMR were treated nasally with either normal saline or 0.6% olopatadine and challenged nasally with a hyperosmolar mannitol solution.

Results: Treatment with 0.6% olopatadine resulted in an improvement in instantaneous nasal symptom scores at 5 and 30 minutes (p < 0.01) compared with baseline and at 30 minutes after hyperosmolar challenge compared with saline-pretreated individuals (p < 0.01). There was also an improvement in nasal peak inspiratory flow rate at 30 minutes after hyperosmolar challenge compared with saline-pretreated individuals (p < 0.01).

Conclusion: In this patient population 0.6% olopatadine appears to be efficacious in symptom reduction in VMR and protects from hyperosmolar challenge.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Capsaicin / administration & dosage
  • Dibenzoxepins / administration & dosage*
  • Dibenzoxepins / adverse effects
  • Disease Progression
  • Female
  • Humans
  • Inspiratory Capacity / drug effects
  • Male
  • Middle Aged
  • Nasal Obstruction / prevention & control
  • Nasal Provocation Tests
  • Nasal Sprays*
  • Olopatadine Hydrochloride
  • Rhinitis, Vasomotor / diagnosis
  • Rhinitis, Vasomotor / drug therapy*
  • Rhinitis, Vasomotor / physiopathology

Substances

  • Dibenzoxepins
  • Nasal Sprays
  • Olopatadine Hydrochloride
  • Capsaicin